Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 18 | - | +19,65 % | ||
| INSMED | 17 | 7 | +8,47 % | ||
| CABALETTA BIO | 11 | - | -4,24 % | ||
| IDEAYA BIOSCIENCES | 8 | 3 | -0,71 % | ||
| PYXIS ONCOLOGY | 8 | - | -4,70 % | ||
| GILEAD SCIENCES | 6 | 5 | -0,17 % | ||
| BIONTECH | 5 | 13 | -0,19 % | ||
| AURINIA PHARMACEUTICALS | 5 | - | +5,15 % | ||
| IMMUNITYBIO | 4 | 3 | +8,98 % | ||
| VIATRIS | 4 | 2 | +2,04 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02:26 | 10 Stocks to Watch Today: QXO, ImmunityBio, PayPay, and More | 1 | Insider Monkey | ||
| 01:30 | Cathie Wood's ARK sells Bullish stock, buys more 10X Genomics | 1 | Investing.com | ||
| 00:35 | Gilead to buy biotech firm Ouro Medicines in over $2 billion deal | 4 | Reuters | ||
| Mo | Galapagos NV: Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases | 391 | GlobeNewswire (Europe) | Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines
New partnership structure would achieve meaningfully improved financial terms... ► Artikel lesen | |
| Mo | Gilead to acquire Ouro Medicines for up to $2.18 billion | 2 | Investing.com | ||
| Mo | Jefferies bestätigt Kaufempfehlung für Cabaletta Bio mit Kursziel von 14 US-Dollar | - | Investing.com Deutsch | ||
| Mo | William Blair reiterates Outperform on Cabaletta Bio stock | 1 | Investing.com | ||
| Mo | Jefferies reiterates Buy on Cabaletta Bio stock, $14 target | 1 | Investing.com | ||
| Mo | William Blair bestätigt 'Outperform'-Einstufung für Cabaletta Bio | 1 | Investing.com Deutsch | ||
| Mo | Absci Q4 2025 Earnings Preview | 1 | Seeking Alpha | ||
| Mo | Abivax S.A. - S-8, Securities to be offered to employees in employee benefit plans | 4 | SEC Filings | ||
| Mo | Abivax S.A. - 20-F, Annual and transition report of foreign private issuers | 6 | SEC Filings | ||
| Mo | Abivax S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Mo | Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings | 2 | Benzinga.com | ||
| Mo | Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Mo | Abivax reports FY results | 4 | Seeking Alpha | ||
| Mo | Jefferies bekräftigt "Buy"-Rating für Supernus Pharmaceuticals | 2 | Investing.com Deutsch | ||
| Mo | Apogee Therapeutics kündigt Aktienemission im Wert von 300 Millionen US-Dollar an | 2 | Investing.com Deutsch | ||
| Mo | Aardvark Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| Mo | Jefferies reiterates Supernus Pharmaceuticals stock Buy rating | 1 | Investing.com |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.